$2.8 billion U.S. peripheral vascular device market to grow to over $5.3 billion by 2016

iData Research Inc.May 11 2010

Peripheral Vascular Device Market to Almost Double by 2016

According to a new report by iData Research (www.idataresearch.net), the leading authority in medical device and pharmaceutical market research, the U.S. peripheral vascular device market is worth $2.8 billion with expected growth to over $5.3 billion by 2016. Increased detection and treatment of abdominal aortic aneurysms (AAAs) and peripheral arterial disease (PAD) are the main drivers of this market, particularly in the stent-graft and peripheral vascular stent segments. These markets are both expected to exceed $1 billion by 2016.

AAAs are a swelling of the aorta, caused by a weakness in the aortic wall. If left untreated, approximately one-third of AAAs will rupture, causing death in 75%-90% of patients. Nearly two million people have aortic aneurysms in the U.S., but only 20% of cases are detected. Improved AAA screening will also lead to increased detection of thoracic aortic aneurysms (TAAs).

"TAA stent-grafts are a relatively new and rapidly growing segment of the peripheral vascular market," says Dr. Kamran Zamanian, CEO of iData, "and are expected to see double-digit growth through 2016."

The report states that the market for peripheral stents, used for treating PAD, has seen strong double-digit growth since 2005, and is expected to grow much faster than the coronary stent market through 2016.

"Public awareness about the threat of PAD, along with growth in new technologies, such as drug-eluting and covered-stents, has been a major driver of growth in the peripheral stent markets," says Dr. Zamanian.

iData's global 3-report series on the "Markets for Peripheral Vascular Devices 2010" covers stents, PTA balloon catheters, atherectomy devices, CTO devices, stent-grafts, surgical-grafts, AV access thrombectomy devices, inferior-vena-cava-filters, catheters, guidewires, introducer sheaths and VCDs. The reports also provide detailed competitive analyses on companies such as Bard (NYSE: BCR), Boston Scientific, Cordis a Johnson & Johnson company (NYSE: JNJ), Cook Medical and W.L. Gore, among many others.